Novel Fabrication of MicroRNA Nanoparticle-Coated Coronary Stent for Prevention of Post-Angioplasty Restenosis

Che, Huilian; Bae, In-Ho; Lim, Kyung Seob; Uthaman, Saji; Song, In Taek; Lee, Haeshin; Lee, Duhwan; Kim, Won Jong; Ahn, Youngkeun; Park, In Kyu

doi:10.4070/kcj.2016.46.1.23

Cited by 17 publications

(13 citation statements)

References 25 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, miR-125 as anti-vascular-proliferative agent in drug eluting stents was shown to reduce in-stent restenosis rate [149]. Also, a knock-down of miR-21 and miR-221 may reduce neointima formation after vessel injury [150].…”

Section: Mirna Therapeutics Via Drug Eluting Stentsmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirna Therapeutics Via Drug Eluting Stentsmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

show abstract

“…The resulting polymer was dialyzed via a molecular weight cutoff (MWCO) 3500 membrane against a 100 mM NaCl solution for 2 days and then against double-distilled water for 2 days. 17) …”

Section: Methodsmentioning

confidence: 99%

The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesHyaluronic acid (HA) is highly biocompatible with cells and the extracellular matrix. In contrast to degradation products of a synthetic polymer, degradation products of HA do not acidify the local environment. The aim of this study was to fabricate an HA-coated paclitaxel (PTX)-eluting stent via simple ionic interactions and to evaluate its effects in vitro and in vivo.Materials and MethodsHA and catechol were conjugated by means of an activation agent, and then the stent was immersed in this solution (resulting in a HA-coated stent). After that, PTX was immobilized on the HA-coated stent (resulting in a hyaluronic acid-coated paclitaxel-eluting stent [H-PTX stent]). Study groups were divided into 4 groups: bare metal stent (BMS), HA, H-PTX, and poly (L-lactide)-coated paclitaxel-eluting stent (P-PTX). Stents were randomly implanted in a porcine coronary artery. After 4 weeks, vessels surrounding the stents were isolated and subjected to various analyses.ResultsSmoothness of the surface was maintained after expansion of the stent. In contrast to a previous study on a PTX-eluting stent, in this study, the PTX was effectively released up to 14 days (a half amount of PTX in 4 days). The proliferation of smooth muscle cells was successfully inhibited (by 80.5±12.11% at 7 days of culture as compared to the control) by PTX released from the stent. Animal experiments showed that the H-PTX stent does not induce an obvious inflammatory response. Nevertheless, restenosis was clearly decreased in the H-PTX stent group (9.8±3.25%) compared to the bare-metal stent group (29.7±8.11%).ConclusionA stent was stably coated with PTX via simple ionic interactions with HA. Restenosis was decreased in the H-PTX group. These results suggest that HA, a natural polymer, is suitable for fabrication of drug-eluting stents (without inflammation) as an alternative to a synthetic polymer.

show abstract

“…[ 82 ] In addition, PEG, disulfide bond, or hyaluronic acid was introduced to PEI‐ or PDA‐MSN hybrid system to improve the stability, stimuli‐responsibility, or the targeting effect of nanoparticle carriers. [ 83,84 ]…”

Section: Ph‐responsive Organic–inorganic Hybrid Nanoparticles For Sirna Deliverymentioning

confidence: 99%

A Review of pH‐Responsive Organic–Inorganic Hybrid Nanoparticles for RNAi‐Based Therapeutics

Wang

Yan

2021

Macromolecular Bioscience

View full text Add to dashboard Cite

RNA interference (RNAi) shows great potential in the treatment of varying cancer and genetic disorders. The lack of safe and effective delivery methods is an ongoing challenge to realize the full potential of RNAi‐based therapeutics. pH‐responsive hybrid nanoparticle is a promising non‐virus platform for small interfering RNA (siRNA) delivery with unique properties including the robust response to the acidic microenvironment and the capability of theranostic and combined therapeutics. The mechanism of RNAi and the delivery barriers for RNAi‐based therapeutics are first discussed. Then, the general patterns of pH‐response and the typical construction of hybrid nanoparticles are demonstrated. The recent advances in pH‐responsive organic–inorganic hybrid nanoparticles for siRNA delivery are highlighted, in particular, how pH‐response of ionizable groups, acid‐labile bonds, and decomposition of inorganic components affect the physicochemical properties of hybrid nanoparticles and benefit the cellular uptake and intracellular trafficking of siRNA payloads are discussed. At last, the remaining problems and the prospects for pH‐responsive hybrid nanoparticles for siRNA delivery are analyzed.

show abstract

Novel Fabrication of MicroRNA Nanoparticle-Coated Coronary Stent for Prevention of Post-Angioplasty Restenosis

Cited by 17 publications

References 25 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model

A Review of pH‐Responsive Organic–Inorganic Hybrid Nanoparticles for RNAi‐Based Therapeutics

Contact Info

Product

Resources

About